National Comprehensive Cancer Network® (NCCN®) is pleased to announce that it is collaborating with Pfizer Global Medical Grants (Pfizer) to offer a new grant opportunity that will support NCCN Member Institution faculty in studies of axitinib. The intent of this RFP is to encourage NCCN Member Institutions to submit clinical research proposals specifically in the treatment of melanoma, hepatocellular carcinoma (HCC) and colorectal cancer (CRC). The Request for Proposals (RFP) clearly outlines the scope and process that will be followed for the submission of proposals. Please note that this document can also be accessed online at http://www.nccn.org/clinical_trials/investigators/default.asp.
The overall aim is to develop innovative trials that will evaluate the role of axitinib in the treatment of melanoma, HCC and CRC. It is hoped proposals submitted in response to this RFP will be useful in guiding further development of axitinib in combinations with other therapies. Studies with correlative objectives will be accepted, but correlative measures alone cannot be the primary endpoint(s).
Deadline: Aug. 12, 2020
Investigators from NCCN Member Institutions
• There is $1.5 Million available for funding. It is anticipated that 2-3 trials will be awarded funding
• There is a maximum of 28% for indirect costs
• General Guidance (inclusive of indirects):
• $500,000 for a multi-institutional trial
• $300,000 for a single institution trial
• Additional funding may be available for exceptional concepts with detailed justification within the budget